New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.48-0.32 (-2.96%)
At close: 04:00PM EDT
10.61 +0.13 (+1.24%)
After hours: 05:53PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 451.25M
Enterprise value 370.81M
Trailing P/E N/A
Forward P/E 4.09
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.40
Price/book (mrq)6.67
Enterprise value/revenue 1.21
Enterprise value/EBITDA -2.53

Trading information

Stock price history

Beta (5Y monthly) 1.22
52-week change 3-30.68%
S&P500 52-week change 318.47%
52-week high 321.86
52-week low 38.82
50-day moving average 310.78
200-day moving average 314.05

Share statistics

Avg vol (3-month) 3883.83k
Avg vol (10-day) 31.02M
Shares outstanding 541.78M
Implied shares outstanding 641.78M
Float 836.64M
% held by insiders 13.12%
% held by institutions 181.30%
Shares short (30 Aug 2023) 410.4M
Short ratio (30 Aug 2023) 414.5
Short % of float (30 Aug 2023) 425.86%
Short % of shares outstanding (30 Aug 2023) 424.89%
Shares short (prior month 30 Jul 2023) 48.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 68.07%
Operating margin (ttm)-21.82%

Management effectiveness

Return on assets (ttm)-8.50%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)306.48M
Revenue per share (ttm)7.70
Quarterly revenue growth (yoy)16.70%
Gross profit (ttm)284.73M
EBITDA -66.52M
Net income avi to common (ttm)-158.79M
Diluted EPS (ttm)-4.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)413.86M
Total cash per share (mrq)9.9
Total debt (mrq)333.41M
Total debt/equity (mrq)493.61%
Current ratio (mrq)2.52
Book value per share (mrq)1.62

Cash flow statement

Operating cash flow (ttm)-96.29M
Levered free cash flow (ttm)-74.11M